{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:08:27Z","timestamp":1792084107073,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.breast.2026.104783","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:57:49Z","timestamp":1775145469000},"page":"104783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Association between diarrhea and survival in patients with HER2-positive advanced breast cancer treated with pyrotinib-based therapy: A landmark analysis from the real-world PRETTY study"],"prefix":"10.1016","volume":"87","author":[{"given":"Yiqun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenna","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxiang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0234-2747","authenticated-orcid":false,"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104783_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.breast.2026.104783_bib2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104783_bib3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus Trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104783_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.breast.2026.104783_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejps.2017.01.021","article-title":"Discovery and development of pyrotinib: a novel irreversible EGFR\/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer","volume":"110","author":"Li","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.breast.2026.104783_bib6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","article-title":"Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Xu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104783_bib7","article-title":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial","volume":"383","author":"Ma","year":"2023","journal-title":"BMJ (Clinical Research ed)"},{"key":"10.1016\/j.breast.2026.104783_bib8","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.19.00108","article-title":"Pyrotinib or lapatinib combined with capecitabine in HER2-Positive metastatic breast cancer with prior taxanes, anthracyclines, and\/or trastuzumab: a randomized, phase II study","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104783_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/tbcr-20-25","article-title":"Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study","volume":"1","author":"Yan","year":"2020","journal-title":"Translat Breast Cancer Res"},{"key":"10.1016\/j.breast.2026.104783_bib10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1186\/s12916-022-02708-3","article-title":"Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial","volume":"20","author":"Wu","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.breast.2026.104783_bib11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104783_bib12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104783_bib13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","article-title":"Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials","volume":"9","author":"Socinski","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104783_bib14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/ijc.34676","article-title":"Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): a nationwide, prospective, observational study","volume":"153","author":"Li","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2026.104783_bib15","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1200\/JCO.2016.69.6179","article-title":"Phase I study and biomarker analysis of pyrotinib, a novel irreversible Pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-Positive metastatic breast cancer","volume":"35","author":"Ma","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104783_bib16","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1158\/1078-0432.CCR-18-4173","article-title":"Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-Positive metastatic breast cancer patients: a phase I clinical trial","volume":"25","author":"Li","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104783_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejca.2022.01.022","article-title":"Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial","volume":"165","author":"Liu","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104783_bib18","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1158\/1078-0432.CCR-22-0446","article-title":"Neoadjuvant trastuzumab and pyrotinib for locally advanced HER2-Positive breast cancer (NeoATP): primary analysis of a phase II study","volume":"28","author":"Yin","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104783_bib19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12916-023-02943-2","article-title":"Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial","volume":"21","author":"Hu","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.breast.2026.104783_bib20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12916-023-02999-0","article-title":"Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial","volume":"21","author":"Cao","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.breast.2026.104783_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105729","article-title":"Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer","volume":"159","author":"Wen","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.breast.2026.104783_bib22","article-title":"Evaluation of the pharmacokinetic interactions of montmorillonite powder or loperamide on pyrotinib in healthy volunteers","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:58:44Z","timestamp":1778925524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":22,"alternative-id":["S0960977626000937"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104783","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between diarrhea and survival in patients with HER2-positive advanced breast cancer treated with pyrotinib-based therapy: A landmark analysis from the real-world PRETTY study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104783"}}